Health Care • Medical Specialities
$208.45 ▲ +3.67
(+1.79%)
MKT CAP: $10.69B • VOL: 1.27M
52W L $121 52W H $245
MOH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $45.43B | $40.65B | $34.07B |
| YoY Revenue Growth % | +11.7% | +19.3% | — |
| Gross Profit | $5.94B | $6.22B | — |
| Gross Margin % | 13.1% | 15.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $781.0M | $1.71B | $1.57B |
| Operating Margin % | 1.7% | 4.2% | 4.6% |
| Net Income (GAAP) | $472.0M | $1.18B | $1.09B |
| EBITDA (Normalized) | $861.8M | $1.79B | $2.80B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$535.0M | $644.0M | $1.66B |
| Capital Expenditures (CapEx) | $101.0M | $100.0M | $1.53B |
| Free Cash Flow (FCF) | -$636.0M | $544.0M | $128.8M |
| FCF Margin % | -1.4% | 1.3% | 0.4% |
| Return on Invested Capital (ROIC %) | 17.2% | 48.9% | 5.0% |
| Cash & Short-Term Equivalents | $4.25B | $4.66B | — |
| Total Debt (Short + Long Term) | $3.77B | $2.92B | $9.57B |
| Total Stockholders' Equity | $4.07B | $4.50B | $19.63B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MOH.